HIV Therapies: Maturation Inhibitor R&D Bears Fruit At ViiV Healthcare
Combination Study With nRTIs Starts
A potent HIV maturation inhibitor has entered Phase IIb at ViiV Healthcare, in combination studies with other antiretrovirals, as the latest potential first-in-class agent to move along the company’s pipeline.
You may also be interested in...
The companies hope the combination of islatravir and lenacapavir will result in best-in-class oral and injectable long-term HIV products. A PrEP combo is a longer-term goal.
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.